Dimensional Fund Advisors LP Acquires 13,653 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ)

Dimensional Fund Advisors LP raised its stake in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) by 58.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 37,190 shares of the company’s stock after purchasing an additional 13,653 shares during the period. Dimensional Fund Advisors LP owned 1.02% of LENZ Therapeutics worth $644,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. American International Group Inc. acquired a new stake in LENZ Therapeutics during the first quarter worth $44,000. Marquette Asset Management LLC acquired a new stake in LENZ Therapeutics in the first quarter worth about $131,000. Rhumbline Advisers grew its position in shares of LENZ Therapeutics by 265.6% during the 2nd quarter. Rhumbline Advisers now owns 16,812 shares of the company’s stock worth $291,000 after buying an additional 12,214 shares during the period. BNP Paribas Financial Markets acquired a new position in shares of LENZ Therapeutics during the 1st quarter worth about $362,000. Finally, BBR Partners LLC acquired a new position in shares of LENZ Therapeutics in the 2nd quarter valued at approximately $346,000. Institutional investors and hedge funds own 54.32% of the company’s stock.

LENZ Therapeutics Stock Performance

Shares of LENZ opened at $24.71 on Monday. The business has a 50-day moving average of $22.89 and a 200-day moving average of $20.11. LENZ Therapeutics, Inc. has a 1 year low of $14.07 and a 1 year high of $29.82.

LENZ Therapeutics (NASDAQ:LENZ) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.09. Sell-side analysts predict that LENZ Therapeutics, Inc. will post -3.15 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on LENZ. Piper Sandler restated an “overweight” rating and issued a $36.00 target price on shares of LENZ Therapeutics in a research note on Thursday, August 15th. William Blair raised LENZ Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. HC Wainwright initiated coverage on LENZ Therapeutics in a report on Monday, August 12th. They set a “buy” rating and a $38.00 target price on the stock. Finally, Raymond James began coverage on LENZ Therapeutics in a research report on Friday, September 27th. They set an “outperform” rating and a $37.00 price objective for the company. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $35.40.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.